| Popis: |
Objective – assessing of the effectiveness of antral and the combination of antral withphytostatin usage regarding to the effect on the state of blood lipid spectrum, glycemia,the degree of insulin resistance in patients with non-alcoholic steatohepatitis (NASH)against the background of obesity with comorbidity with chronic obstructive pulmonarydisease (COPD).Materials and methods. 90 NASH patients with obesity of I degree and COPD 2-3 D wereexamined: 25 patients (group 1 – control group) received basic NASH therapy (Esentsialeforte N (Sanofi Avensis / Nutterman and Cie GmbH) 300 mg, 2 caps., 3 times per day)60 days and COPD therapy (Symbicort Turbuhaler (budesonide 160 mg/d + formoterolfumarate 4,5 mg/s) (AstraZeneca AB, Sweden) inhaled 2 times per day for 60 days,Berodual (ipratropium / fenoterol (250/500 mg/ml) (Institute de Angele Italy / BoehringerIngelheim International GmbH) nebulizer inhalation 2 times per day, azithromycin(Azithro Sandoz, Ukraine Sandoz) 500 mg, 1 time per day for 10 days). The second group(basic group, 2) consisted of 35 NASH patients with obesity of I degree and COPD 2-3D, in addition to the same basic COPD therapy, they received Antral (Farmak, Ukraine) 200 mg, 3 times per day for 60 days as a hepatoprotector. The third group (basic group,3) included 30 NASH patients with obesity of I degree and COPD 2-3 D, except the samebasic COPD treatment, they received Antral (Farmak, Ukraine) 200 mg, 3 times per dayas a hepatoprotector, and Phytostatin (Polyconazole) (OmniFarma LLC, Ukraine) 20 mgafter dinner during 60 days. The average age of patients was (55,7 ± 3,22) years. Thecontrol group consisted of 30 apparently healthy persons (AHP).Results. The concentration of total lipids in blood of patients from the 1st group aftertreatment has not decreased significantly and exceeded the normative data (p |
